MedPath

A DOUBLE-BLIND, DOSE-RANGE, PLACEBO CONTROLLED STUDYOF THE EFFECTS OF PST2238 VS. PLACEBO IN PATIENTSWITH STABLE, UNCOMPLICATED, ESSENTIAL HYPERTENSION.

Conditions
Essential Hypertension
MedDRA version: 6,1Level: LLTClassification code 10015488
Registration Number
EUCTR2004-000415-26-IT
Lead Sponsor
SIGMA-TA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
440
Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath